Literature DB >> 1500196

Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes.

A B Petrov1, B F Semenov, Y P Vartanyan, M M Zakirov, V P Torchilin, V S Trubetskoy, N V Koshkina, V L L'Vov, I K Verner, I V Lopyrev.   

Abstract

To obtain nontoxic and highly immunogenic lipopolysaccharide (LPS) for immunization, we incorporated Neisseria meningitidis LPS into liposomes. Native LPS and its salts were incorporated by the method of dehydration-rehydration of vesicles or prolonged cosonication. The most complete incorporation of LPS into liposomes and a decrease in toxicity were achieved by the method of dehydration-rehydration of vesicles. Three forms of LPS (H+ form, Mg2+ salt, and triethanolamine salt) showed different solubilities in water, the acidic form of LPS, with the most pronounced hydrophobic properties, being capable of practically complete association with liposomal membranes. An evaluation of the activity of liposomal LPS in vitro (by the Limulus amoebocyte test) and in vivo (by monitoring the pyrogenic reaction in rabbits) revealed a decrease in endotoxin activity of up to 1,000-fold. In addition, the pyrogenic activity of liposomal LPS was comparable to that of a meningococcal polysaccharide vaccine. Liposomes had a pronounced adjuvant effect on the immune response to LPS. Thus, the level of anti-LPS plaque-forming cells in the spleens of mice immunized with liposomal LPS was 1 order of magnitude higher and could be observed for a longer time (until day 21, i.e., the term of observation) than in mice immunized with free LPS. The same regularity was revealed in a study done with an enzyme-linked immunosorbent assay. This study also established that antibodies induced by immunization belonged to the immunoglobulin M and G classes, which are capable of prolonged circulation. Moreover, liposomal LPS induced a pronounced immune response in CBA/N mice (defective in B lymphocytes of the LyB-5+ subpopulation). The latter results indicate that the immunogenic action of liposomal LPS occurs at an early age.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500196      PMCID: PMC257405          DOI: 10.1128/iai.60.9.3897-3903.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Pertussis Vaccine Prepared with Phase-I Cultures Grown in Fluid Medium.

Authors:  S M Cohen; M W Wheeler
Journal:  Am J Public Health Nations Health       Date:  1946-04

Review 2.  Immunological adjuvants: a role for liposomes.

Authors:  G Gregoriadis
Journal:  Immunol Today       Date:  1990-03

3.  Production of antibody to lipopolysaccharide (LPS) after immunization with a LPS-polymyxin B-agarose immunogen.

Authors:  L K Ryan; M H Karol
Journal:  J Appl Bacteriol       Date:  1988-06

4.  Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide.

Authors:  M Pollack; J K Chia; N L Koles; M Miller; G Guelde
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

5.  Endotoxic-lipopolysaccharide-specific binding proteins on lymphoid cells of various animal species: association with endotoxin susceptibility.

Authors:  D J Roeder; M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

6.  Immunization against experimental murine salmonellosis with liposome-associated O-antigen.

Authors:  J V Desiderio; S G Campbell
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

7.  A procedure for the efficient incorporation of wild-type lipopolysaccharide into liposomes for use in immunological studies.

Authors:  J Dijkstra; J L Ryan; F C Szoka
Journal:  J Immunol Methods       Date:  1988-11-10       Impact factor: 2.303

8.  The immunogenicity and antigenicity of lipid A are influenced by its physicochemical state and environment.

Authors:  L Brade; K Brandenburg; H M Kuhn; S Kusumoto; I Macher; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

9.  Outer membrane of Salmonella typhimurium. Electron spin resonance studies.

Authors:  H Nikaido; Y Takeuchi; S I Ohnishi; T Nakae
Journal:  Biochim Biophys Acta       Date:  1977-02-14

10.  Electromorphic characterization and description of conserved epitopes of the lipooligosaccharides of group A Neisseria meningitidis.

Authors:  J J Kim; R E Mandrell; Z Hu; M A Westerink; J T Poolman; J M Griffiss
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

View more
  10 in total

Review 1.  In-depth conversation: spectrum and kinetics of neuroimmune afferent pathways.

Authors:  Ning Quan
Journal:  Brain Behav Immun       Date:  2014-02-22       Impact factor: 7.217

2.  Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.

Authors:  Noëlle Mistretta; Bruno Guy; Yves Bérard; François Dalençon; Olivia Fratantonio; Christophe Grégoire; Aurélie Lechevallier; Philippe Lhéritier; Laurent Revet; Monique Moreau; Jean Haensler; Bachra Rokbi
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 3.  Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.

Authors:  Stacey L Demento; Alyssa L Siefert; Arunima Bandyopadhyay; Fiona A Sharp; Tarek M Fahmy
Journal:  Trends Biotechnol       Date:  2011-04-02       Impact factor: 19.536

4.  Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine.

Authors:  E Bennett-Guerrero; T J McIntosh; G R Barclay; D S Snyder; R J Gibbs; M G Mythen; I R Poxton
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 5.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

6.  Meningococcal group A lipooligosaccharides (LOS): preliminary structural studies and characterization of serotype-associated and conserved LOS epitopes.

Authors:  J J Kim; N J Phillips; B W Gibson; J M Griffiss; R Yamasaki
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.

Authors:  Jesús Arenas; Harry van Dijken; Betsy Kuipers; Hendrik Jan Hamstra; Jan Tommassen; Peter van der Ley
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

8.  Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy.

Authors:  Stacey L Demento; Stephanie C Eisenbarth; Harald G Foellmer; Craig Platt; Michael J Caplan; W Mark Saltzman; Ira Mellman; Michel Ledizet; Erol Fikrig; Richard A Flavell; Tarek M Fahmy
Journal:  Vaccine       Date:  2009-04-03       Impact factor: 3.641

9.  Cellular immune responses to Neisseria meningitidis in children.

Authors:  A J Pollard; R Galassini; E M Rouppe van der Voort; M Hibberd; R Booy; P Langford; S Nadel; C Ison; J S Kroll; J Poolman; M Levin
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

10.  Controlled progressive innate immune stimulation regimen prevents the induction of sickness behavior in the open field test.

Authors:  Qun Chen; Andrew J Tarr; Xiaoyu Liu; Yufen Wang; Nathaniel S Reed; Cameron P Demarsh; John F Sheridan; Ning Quan
Journal:  J Inflamm Res       Date:  2013-07-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.